Atlas Trials

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

Clinical trial NCT05794958 · RECRUITING

Trial details

NCT number
NCT05794958
Sponsor
Stanford University
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Non-Hodgkin LymphomaLarge B-cell Lymphoma
Start date
2023-05-23
Primary completion
2038-04-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.